Report
Summit Therapeutics stock surges after AstraZeneca reveals $2 billion investment
Barron's says the deal would give AstraZeneca exposure to a cancer treatment it describes as promising, without buying Summit outright.
TLDR
Barron's reports that Summit Therapeutics stock surged after AstraZeneca revealed a $2 billion investment. It says the deal would give AstraZeneca exposure to a cancer treatment it describes as promising, without acquiring the company outright.
Combined views
32.7K
2 Sources, first seen ago
